New Zealand markets close in 25 minutes
  • NZX 50

    11,281.07
    +46.02 (+0.41%)
     
  • NZD/USD

    0.5949
    +0.0036 (+0.61%)
     
  • NZD/EUR

    0.5645
    +0.0021 (+0.38%)
     
  • ALL ORDS

    7,119.80
    +37.60 (+0.53%)
     
  • ASX 200

    6,928.20
    +38.00 (+0.55%)
     
  • OIL

    84.75
    +0.53 (+0.63%)
     
  • GOLD

    1,841.10
    +6.30 (+0.34%)
     
  • NASDAQ

    14,776.25
    +210.64 (+1.45%)
     
  • FTSE

    7,412.45
    -57.71 (-0.77%)
     
  • Dow Jones

    33,129.55
    +127.17 (+0.39%)
     
  • DAX

    15,099.92
    +14.71 (+0.10%)
     
  • Hang Seng

    17,303.10
    +107.26 (+0.62%)
     
  • NIKKEI 225

    30,886.51
    +359.63 (+1.18%)
     
  • NZD/JPY

    88.3390
    +0.2800 (+0.32%)
     

Better Gene Sequencing Stock: Illumina vs. Bionano Genomics

Better Gene Sequencing Stock: Illumina vs. Bionano Genomics

Illumina (NASDAQ: ILMN) and Bionano Genomics (NASDAQ: BNGO) might both make gene sequencing devices, but as investments the two couldn't be more different. Whereas Bionano is a new entrant to the market and still has a lot to prove to its investors as well as the scientific community, Illumina is the top dog that's fighting to maintain its position. Bulls argue that Illumina is the better gene sequencing stock because in some sequencing markets, it's basically the only option in town, particularly in the all-important market for next generation sequencers (NGS).